Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer

Breast Cancer Research and Treatment

Volumn 154, Issue 1, 2015, Pages 133-143

  Calip, Gregory S ^a,b,c   Malmgren, Judith A ^c,d   Lee, Wan Ju ^a   Schwartz, Stephen M ^b,c   Kaplan, Henry G ^e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d HealthStat Consulting Inc   (United States)

^e SWEDISH MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Adjuvant chemotherapy; Breast cancer; Granulocyte colony stimulating factors; Myelodysplastic syndrome

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FILGRASTIM; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PEGFILGRASTIM; ANTHRACYCLINE; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CHEMORADIOTHERAPY; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; ACUTE MYELOID LEUKEMIA; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; BREAST NEOPLASMS; CANCER STAGING; CHEMICALLY INDUCED; COMPLICATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTHRACYCLINES; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS;

EID: 84945442787     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3590-1     Document Type: Article

References (54)

1. Godley LA, Larson RA (2008) Therapy-related myeloid leukemia. Semin Oncol 35(4):418–429. doi:10.1053/j.seminoncol.2008.04.012
2. Larson RA (2007) Etiology and management of therapy-related myeloid leukemia. Hematol Am Soc Hematol Educ Program. doi:10.1182/asheducation-2007.1.453
3. Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE (2015) Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol 33(4):340–348. doi:10.1200/JCO.2013.54.6119
4. Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH (2007) Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 25(25):3871–3876. doi:10.1200/JCO.2007.12.0832
5. Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D (2005) Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23(18):4179–4191. doi:10.1200/JCO.2005.05.029
6. Smith RE, Bryant J, DeCillis A, Anderson S (2003) Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21(7):1195–1204
7. Kaplan H, Malmgren J, De Roos AJ (2013) Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study. Breast Cancer Res Treat 137(3):863–867. doi:10.1007/s10549-012-2386-9
8. Kaplan HG, Malmgren JA, Atwood MK (2011) Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990–2005. BMC Cancer 11:260. doi:10.1186/1471-2407-11-260
9. Felix CA (1998) Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1400(1–3):233–255
10. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P (1995) Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86(9):3542–3552
11. Du XL, Lairson DR, Begley CE, Fang S (2005) Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort. J Clin Oncol 23(34):8620–8628. doi:10.1200/JCO.2005.02.6252
12. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR (2007) Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99(3):196–205. doi:10.1093/jnci/djk028
13. Lyman GH, Dale DC, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM, Crawford J (2010) Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 28(17):2914–2924. doi:10.1200/JCO.2009.25.8723
14. Lyman GH (2005) Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Cancer Netw 3(4):557–571
15. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187–3205. doi:10.1200/JCO.2006.06.4451
16. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for R, Treatment of C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32. doi:10.1016/j.ejca.2010.10.013
17. Rajan SS, Stearns SC, Lyman GH, Carpenter WR (2011) Effect of primary prophylactic G-CSF use on systemic therapy administration for elderly breast cancer patients. Breast Cancer Res Treat 130(1):255–266. doi:10.1007/s10549-011-1553-8
18. Kaushansky K (2006) Lineage-specific hematopoietic growth factors. N Engl J Med 354(19):2034–2045. doi:10.1056/NEJMra052706
19. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431–1439. doi:10.1200/JCO.2003.09.081
20. Kaplan HG, Malmgren JA, Li CI, Calip GS (2013) Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors. Breast Cancer Res Treat 142(3):629–636. doi:10.1007/s10549-013-2773-x
21. Martin MG, Welch JS, Luo J, Ellis MJ, Graubert TA, Walter MJ (2009) Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat 118(3):593–598. doi:10.1007/s10549-009-0376-3
22. Schumock GT, Li EC, Suda KJ, Matusiak LM, Hunkler RJ, Vermeulen LC, Hoffman JM (2014) National trends in prescription drug expenditures and projections for 2014. Am J Health-Syst Pharm 71(6):482–499. doi:10.2146/ajhp130767
23. Surveillance Epidemiology and End Results (SEER) Program Overview of the SEER Program http://seer.cancer.gov/about/overview.html
24. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):IV-3–IV-18. doi:10.1097/01.MLR.0000020942.47004.03
25. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL (2003) Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin N Am 83(4):803–819. doi:10.1016/S0039-6109(03)00034-3
26. Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS (2013) Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst 105(19):1456–1462. doi:10.1093/jnci/djt211
27. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619
28. Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53(12):1258–1267
29. Bikov KA, Mullins CD, Seal B, Onukwugha E, Hanna N (2013) Algorithm for identifying chemotherapy/biological regimens for metastatic colon cancer in SEER-medicare. Med Care. doi:10.1097/MLR.0b013e31828fad9f
30. Ma X, Does M, Raza A, Mayne ST (2007) Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109(8):1536–1542. doi:10.1002/cncr.22570
31. Cogle CR, Craig BM, Rollison DE, List AF (2011) Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 117(26):7121–7125. doi:10.1182/blood-2011-02-337964
32. Wakeford R (2004) The cancer epidemiology of radiation. Oncogene 23(38):6404–6428. doi:10.1038/sj.onc.1207896
33. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN (1992) Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326(26):1745–1751. doi:10.1056/NEJM199206253262605
34. Campone M, Roche H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P, Namer M, Monnier A, Montcuquet P, Goudier MJ, Fumoleau P (2005) Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. Ann Oncol 16(8):1343–1351. doi:10.1093/annonc/mdi251
35. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulie P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Geneve J, Asselain B (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24(36):5664–5671. doi:10.1200/JCO.2006.07.3916
36. Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27(8):1177–1183. doi:10.1200/JCO.2008.18.4028
37. Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O’Brien P, Shepherd LE (2010) Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol 28(1):77–82. doi:10.1200/JCO.2009.22.1077
38. Tallman MS, Gray R, Bennett JM, Variakojis D, Robert N, Wood WC, Rowe JM, Wiernik PH (1995) Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol 13(7):1557–1563
39. Amgen, Inc. (2013) Neupogen (product monograph). Thousand Oaks: Amgen, Inc
40. Dong F, Brynes RK, Tidow N, Welte K, Lowenberg B, Touw IP (1995) Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 333(8):487–493. doi:10.1056/NEJM199508243330804
41. Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B, Fier C, Freedman M, Kannourakis G, Kinsey S, Schwinzer B, Zeidler C, Welte K, Dale DC, Severe Chronic Neutropenia International R (2006) The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 107(12):4628–4635. doi:10.1182/blood-2005-11-4370
42. Touw IP, Bontenbal M (2007) Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst 99(3):183–186. doi:10.1093/jnci/djk057
43. Naparstek E (1995) Granulocyte colony-stimulating factor, congenital neutropenia, and acute myeloid leukemia. N Engl J Med 333(8):516–518. doi:10.1056/NEJM199508243330811
44. Shapira MY, Kaspler P, Samuel S, Shoshan S, Or R (2003) Granulocyte colony stimulating factor does not induce long-term DNA instability in healthy peripheral blood stem cell donors. Am J Hematol 73(1):33–36. doi:10.1002/ajh.10324
45. Confer DL, Miller JP (2007) Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 137 (1):77–78; author reply 79–80. doi:10.1111/j.1365-2141.2007.06524.x
46. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS (2006) Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 135(5):642–650. doi:10.1111/j.1365-2141.2006.06312.x
47. Shaw BE, Confer DL, Hwang W, Pulsipher MA (2015) A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. Bone Marrow Transplant 50(3):334–340. doi:10.1038/bmt.2014.278
48. Slovak ML, Bedell V, Lew D, Albain KS, Ellis GK, Livingston RB, Martino S, Perez EA, Hortobagyi GN, Sher D, Stock W (2010) Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Res Treat 119(2):391–398. doi:10.1007/s10549-009-0597-5
49. Amgen, Inc. (2013) Neulasta (product monograph). Thousand Oaks: Amgen, Inc
50. Molineux G, Arvedson T, Foote M (2012) Twenty years of G-CSF: clinical and nonclinical discoveries. Milestones in drug therapy. Springer, Basel
51. Rizzieri DA, O’Brien JA, Broadwater G, Decastro CM, Dev P, Diehl L, Beaven A, Lagoo A, Gockerman JP, Chao NJ, Moore JO (2009) Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. Cancer 115(13):2922–2929. doi:10.1002/cncr.24379
52. Kroger N, Brand R, van Biezen A, Cahn JY, Slavin S, Blaise D, Sierra J, Zander A, Niederwieser D, de Witte T, Myelodysplastic Syndromes Subcommittee of The Chronic Leukaemia Working Party of the European Group for B, Marrow T (2006) Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 37(2):183–189. doi:10.1038/sj.bmt.1705226
53. Anderson JE, Gooley TA, Schoch G, Anasetti C, Bensinger WI, Clift RA, Hansen JA, Sanders JE, Storb R, Appelbaum FR (1997) Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood 89(7):2578–2585
54. Early Breast Cancer Trialists’ Collaborative G (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0